knowledge -WSS

knowledge

author：entertainment 2025-09-28 23:48:24 - browse：54639

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Adopting new red light myopia treatments may be short

entertainment

WSS

Curing rare childhood diseases will falter unless Congress steps up

The CDC's new social media misinformation war

AstraZeneca stays mum on Medicare drug pricing negotiations

A single Democrat is willing to weaken Medicare negotiation power

Stephen Quake on the Chan Zuckerberg quest to conquer disease

The CDC's new social media misinformation war

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

Cancer drug shortages should be causing more outrage

'Essentially witchcraft:' A former naturopath takes on the field

DIEP, the 'gold standard' of breast reconstruction, is under threat

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Heart attack and stroke risk calculators need revising

What’s missing from the debate over nursing home staff minimums

Guidelines to prevent youth baseball injuries need more muscle

Texas Medical Board asked to define abortion emergency exception

Psychedelics group wrestles with new pharma identity

Curing rare childhood diseases will falter unless Congress steps up

hotspot

How faith leaders like me can help address America's obesity epidemic

Readers discuss the intersection of pregnancy and addiction

What’s missing from the debate over nursing home staff minimums

A single Democrat is willing to weaken Medicare negotiation power

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

How faith leaders like me can help address America's obesity epidemic

hotspot

knowledge

entertainment

knowledge